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Pistacia integerrima is one of twenty species among the genus Pistacia. Long horn-shaped galls that develop on this plant are
harvested and used in Ayurveda and Indian traditional medicine to make “karkatshringi”, a herbal medicine used for the treatment
of asthma and different disorders of respiratory tract. However, until now, the molecular mechanisms of action of “karkatshringi”
and its chemical characterization are partially known. This study deals with the isolation and characterization of the active
constituents from themethanolic extract ofP. integerrima galls and it was also oriented to evaluate in vitro and in silico their potential
enzymatic inhibitory activity against phosphodiesterase-1 (PDE1), a well-known enzyme involved in airway smoothmuscle activity
and airway inflammation. Our results showed that the methanolic extract of P. integerrima galls and some of its active constituents
[naringenin (1) and 3,5,7,4󸀠-tetrahydroxy-flavanone (2)] are able in vitro to inhibit PDE1 activity (59.20± 4.95%, 75.90± 5.90%, and
65.25± 5.25%, resp.) and demonstrate in silico an interesting interaction with this enzymatic site. Taken together, our results add
new knowledge of chemical constituents responsible for the biological activity of P. integerrima and contextually legitimate the use
of this plant in folk medicine.
1. Introduction
The importance of medicinal plants and their derivate in the
treatment of various ailments is well known. However, many
ethnopharmacological uses are yet to be justified scientifically
for a rational and safe use. In this context, plants belonging to
Pistacia genus (family Anacardiaceae) have attracted the
attention of botanists, chemists, and pharmacologists since
long time ago [1].
P. integerrima J. L. is one of twenty species among the
genus Pistacia distributed in Himalaya as well as in various
regions of Pakistan and India. This plant grows at an altitude
of ∼3000 meters reaching a height of ∼18 meters [2, 3].
Long horn-shaped galls that develop on this plant are har-
vested and used in Ayurveda and Indian traditional medicine
to make “karkatshringi,” an herbal medicine used for the
treatment of various ailments including asthma and different
disorders of respiratory tract [4–8].
In line with these observations, recent investigations have
also demonstrated that essential oils and galls aqueous extract
of P. integerrima possess an antiasthmatic activity due to the
inhibition of histamine release, 5-lipoxygenase activity, and
mast cell stabilization [9, 10]. The main constituents isolated
fromdifferent parts of P. integerrima are represented by triter-
penoids, sterols, and phenols [11, 12].
On this basis, this study deals with the isolation and char-
acterization of the active constituents from the methanolic
extract of P. integerrima galls and it was also oriented to
evaluate their potential enzymatic inhibitory activity against
phosphodiesterase-1 (PDE1), a well-known enzyme involved
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Figure 1: Structure of naringenin (1) and 3,5,7,4󸀠-tetrahydroxy-flavanone (2).
in airway smooth muscle activity and airway inflammation
[13, 14]. To clarify this aspect, here we have also performed
molecular docking studies of these compounds on PDE1
binding site.
2. Materials and Methods
2.1. Reagents. Snake venom phosphodiesterase I (P4631),
caffeine (C0750), and bis-(p-nitrophenyl) phosphate (N3002)
were purchased from Sigma-Aldrich Co. (Milan, Italy).
Organic solvents such as n-hexane, chloroform, ethyl acetate,
and n-butanol were obtained from Suzhou Ausun Chemical
Co., Lit. (Suzhou,China).Unless otherwise stated, all the other
reagents were from Searle Pakistan Ltd. (Karachi, Pakistan).
2.2. PlantMaterial. P. integerrimawas collected fromMurree
Hills (Pakistan) and it was successively identified by Professor
Rashid A. (Department of Botany, University of Peshawar,
Pakistan). A voucher specimen (number 20037) was
deposited at Department of Botany, University of Peshawar,
Pakistan.
2.3. Extraction and Isolation. Coarsely powdered galls of P.
integerrima (∼14 kg) were subjected to maceration at room
temperature for 7 dayswithmethanol/water (50 : 50, v/v).The
residue was heated under pressure in a water bath at 40∘C
for further thickening to yield the crude extract (∼600 g) and
then subjected to chromatography over silica gel and finally
eluted with a mixture of methanol/chloroform (100 : 0→
0 : 95). The resulting fractions were combined in 10 different
subfractions (PS-1 to PS-10) on the basis of TLC. Subse-
quently, fraction PS-10 (obtained at the elution step 100 : 0→
5 : 99, methanol/chloroform) was subjected to repeated chro-
matography and TLC column in order to obtain the isolated
compounds 1 and 2 (Figure 1) and fraction PS8 (obtained at
the elution step 100 : 0→ 5 : 99, 𝑛-hexane/ethyl acetate) led
to the isolation of some known constituents such as 𝛽-
sitosterol (compound 3), 𝛽-stigmasterol (compound 4), and
pistagremic acid (compound 5). Their structures were estab-
lished by comparing their spectral data and physical con-
stants with data already present in literature [15–17].
2.4. Phosphodiesterase I Inhibition Assay. Activity against
snake venom phosphodiesterase I was assayed by using the
reported method [18] with the following modifications:
33mM Tris-HC1 buffer pH 8.8, 30mM Mg-acetate with
0.742mU/well of PDE1 and 0.33mM bis-(p-nitrophenyl)
phosphate as substrate (vehicle). EDTA (0.2mM)was used as
positive controls [19, 20]. After 30 min incubation of the
enzyme with the test samples (0.2mg/mL and 0.2mM for
methanolic fraction and compounds 1–5, resp.), enzyme
activity was monitored spectrophotometrically at 37∘C on a
microplate reader (SpectraMax, Molecular Devices, CA,
USA) by following the rate (change in OD/min) of release of
p-nitrophenol from p-nitrophenyl phosphate at 410 nm. All
assays were conducted in triplicate.
2.5. Computational Analysis. The 3D structure of phospho-
diesterase protein was downloaded from protein data bank
(PDB) with accession code of 3HMV. The structure was
energy minimized through Swiss pdb viewer v4.1.0 program
implemented with GROMOS96 force field [21]. The struc-
tures of compound 1, compound 2, and caffeine were drawn
in theChem sketch software [22].These structures were saved
inmol format and, after hydrogen bind addition, energymin-
imization was carried out through Avogadro software [23].
The docking studies were carried out throughAutodock Vina
[24] and i-GEMDOCKv 2.1 [25]. For Autodock Vina the sol-
ventmolecules were removed from the 3Dphosphodiesterase
protein and hydrogen atoms addition was calculated [26].
The ligand molecules pdb files were then uploaded in PyRex
virtual screening tool [27], connected with Autodock Vina,
and then converted into pdbqt format, merging nonpolar
hydrogens and adding Gasteiger charges. Charge deficit was
spread over all atoms of related residues. Grid center was
placed on the active site of the phosphodiesterase protein.
We chose coordinates and dimensions along 𝑥, 𝑦, and 𝑧 axes
of the grid related to the site of presumed pharmacological
interest. In particular, we chose a grid box size of 28 × 28 ×
28 centered at 𝑥 = −13, 𝑦 = −27, and 𝑧 = −6 with
spacing of 1.0 A˚ between the grid points [28]. Moreover, i-
GEMDOCKv2.1 software was also used for docking studies.
The best docking conformations were performed twice and
implemented with genetic evolutionary algorithm empirical
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scoring function. Binding pocket was recognized at a distance
of 8 A˚. Empirical scoring function was estimated as follows:
fitness = vdW + Hbond + Elec., where the vdW, Hbond, and
Elec. terms represented van derWaal energy, hydrogen bind-
ing energy, and electrostatistic energy, respectively [29].
2.6. Statistical Analysis. The results obtained were expressed
as mean ± S.E.M. For statistical analysis, ANOVA was fol-
lowed by post hoc Dunnett’s test for multiple comparisons. In
some case, one sample 𝑡-test was used to evaluate significance
against the hypothetical zero value. Values were considered to
be significant at 𝑃 ≤ 0.05.
3. Results and Discussion
In our study, we have isolated two flavonoids, naringenin and
3,5,7,4󸀠-tetrahydroxy-flavanone (compounds 1-2, Figure 1),
and three pentacyclic triterpenes (compounds 3, 4, and 5)
from themethanolic extract of P. integerrima galls.The struc-
tures of compounds 1-2 were elucidated by spectroscopic
analyses including 1D and 2D NMR experiments (see Sup-
plementary Figures 1, 2, and 3 resp., in Supplementary Mate-
rial available online at http://dx.doi.org/10.1155/2015/506564),
whereas those of compounds 3, 4, and 5 were established by
comparing their spectral data and physical constants with
data already present in literature (Supplementary Figure 3)
[15–17].
Compound 1 was isolated as a pale yellow solid. The
molecular formula of compound 1was identified asC
15
H
12
O
6
by HR-EI-MS, EIMS, and ESI spectrum. IR (KBr, ]max in
cm−1): 3599, 1665, 2922, 1591, and 1463. UV 𝜆max (nm): 340
and 264. 1H NMR (600MHz, MeOD) 𝛿H: 5.32 (1H, d, H-
2,𝑗 = 2.0Hz), 5.78 (1H, d, H-3, 𝑗 = 2.0Hz), 6.23 (1H, d,
H-6, 𝑗 = 8.8Hz), 6.85 (1H, d, H-8, 𝑗 = 8.8Hz), 7.11 (1H, d,
H-2󸀠, 𝑗 = 8.8Hz), 6.82 (1H, d, H-3󸀠, 𝑗 = 8.8Hz), 6.82 (1H,
d, H-5󸀠, j = 1.2Hz), and 7.11 (1H, m, H-6, 𝑗 = 10.2) respec-
tively; 13C NMR (CDCl
3
, 150MHz) 𝛿c: 83.4 (C, C-2), 71.2
(C, C-3), 193.0 (C, C-4), 161.9 (C, C-5), 104.1 (C, C-6), 165.7
(C, C-7), 95.5 (CH, C-8), 158.5 (C, C-9), 104.0 (C, C-10), 130.9
(C, C-1󸀠), 129.9 (CH, C-2󸀠), 117.0 (CH, C-3󸀠), 158.5 (C, C-4󸀠),
117.0 (CH, C-5󸀠), 129.9 (CH, C-6󸀠). The EI showed peak at
m/z 288, formula C
15
H
12
O
6
. On the basis of the spectral data,
compound 1 was identified as naringenin [30].
Similarly, compound 2was isolated as a pale yellow solid.
The molecular formula of this compound was identified as
C
15
H
12
O
5
by HR-EI-MS, EIMS, and ESI spectrum (Sup-
plementary Figure 2). IR (KBr, ]max in cm
−1): 3599, 1665,
2922, 1591, and 1463. UV 𝜆max (nm): 340 and 264.
1H NMR
(600MHz, MeOD) 𝛿H: 5.95 (1H, d, H-2, 𝑗 = 14.0Hz), 3.64,
2.74 (2H, dd, 𝑗 = 2.4; 15.1), 6.51 (1H, d, H-6, 𝑗 = 1.8Hz), 6.63
(1H, d, H-8, 𝑗 = 2.4Hz), 7.11, (1H, d, H-2󸀠, 𝑗 = 10.2Hz), 6.82,
(1H, d, H-3󸀠, 𝑗 = 10.2Hz), 6.82 (1H, d, H-5󸀠, 𝑗 = 10.2Hz), and
7.11 (1H, d,H-6󸀠, 𝑗 = 10.2Hz), respectively; 13CNMR(CDCl
3
,
150MHz) 𝛿: 83.5 (C, C-2), 44.4 (C, C-3), 194.4 (C, C-4), 161.7
(C, C-5), 96.1 (C, C-6), 165.6 (C, C-7), 96.4 (CH, C-8), 158.2
(C, C-9), 104.1 (C, C-10), 130.8 (C, C-1󸀠), 127.8 (CH, C-2󸀠),
116.9 (CH, C-3󸀠), 159.2 (C, C-4󸀠), 116.9 (CH, C-5󸀠), 127.8 (CH,
C-6󸀠).The EI showed peak atm/z 272, formula C
15
H
12
O
5
. On
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Figure 2: Phosphodiesterase I inhibitory activity (expressed in %)
of themethanolic fraction (MeOH, 0.2mg/mL) of P. integerrima and
of the isolated compounds 1–5 (0.2mM). The assay was performed
in presence of positive control EDTA (0.2mM). Data are expressed
as mean ± S.E.M. ∗∗𝑃 < 0.01 versus vehicle. Data are representative
of three different experiments.
the basis of the spectral data, compound 2 was identified as
3,5,7,4󸀠-tetrahydroxy-flavanone.
Naringenin is a hydroxylated flavanone common in
grapefruit and other Citrus species. This compound is con-
sidered to have bioactive effects on human health as antioxi-
dant, free radical scavenger, anti-inflammatory, carbohydrate
metabolism promoter, and immune system modulator [31].
3,5,7,4󸀠-Tetrahydroxy-flavanone is a quite rare compound,
found in Euonymus alatus (Thunb.) Siebold (Celastraceae)
and in Sygyzium cuminii L. seeds [32].
Recent investigations have demonstrated that essential
oils and galls aqueous extract of P. integerrima possess an
antiasthmatic activity due to the inhibition of histamine
release, 5-lipoxygenase activity, and mast cell stabilization
[9, 10]. In addition to these mechanisms, we have taken into
account the possibility that the antiasthmatic activity of this
plant could be also mediated by the inhibition of phospho-
diesterase enzymes (PDEs). Only a few inhibitors of PDE1
have been reported so far and the majority of them, with the
exception of rare examples [20], are of synthetic origin.
To this aim, we have tested the methanolic extract and
its constituents against snake venom phosphodiesterase I,
comparing their inhibitory activities with those of caffeine,
a well-known nonselective PDEs inhibitor [33–35].
Phosphodiesterases (PDEs) are a family of enzymes that
catalyze the breakdown of the second messengers cGMP and
cAMP [36, 37]. The PDE family has been a focus of drug
development in recent years, especially for cardiovascular and
airway diseases because of the favorable effects that second
messengers have in the vasculature which include increasing
vasodilation and decreasing of smooth muscle cells prolifer-
ation [38–41]. Recent investigations have also demonstrated
that systemic phosphodiesterase inhibitors administration
could ameliorate bronchodilation and reduce airway inflam-
mation [13, 14]. The results reported in Figure 2 indicate that
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Figure 3: 2D (a) and 3D (b) models of naringenin (1) in the binding site of PDE1. Green lines indicate hydrogen bonds and the half-moon
the hydrophobic interactions.
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Figure 4: 2D (left) and 3D (right) models of 3,5,7,4󸀠-tetrahydroxy-flavanone (2) in the binding site of PDE1. Green lines indicate hydrogen
bonds and the half-moon the hydrophobic interactions.
methanol extract and compounds 1 and 2 possess a significant
inhibitory activity against PDE1 enzyme (59.20± 4.95%, 75.90
± 5.90%, and 65.25 ± 5.25% of PDE1, resp.) whereas com-
pounds 3, 4, and 5 displayed only partial inhibitory activities
(8.05 ± 3.05, 8.20 ± 3.20, and 10.70 ± 4.00%, resp.). The assay
was performed in presence of positive control EDTA (85.05
± 4.95 % of PDE1 inhibitory activity). Successively, we have
investigated by docking studies the interaction of compounds
1 and 2 with the binding site of PDE1. Figure 3 shows the
interaction of compound 1 (naringenin) with PDE1 enzyme
binding pocket.These interactions including hydrogen bonds
formed by Thr256 (with a distance of 3.02 A˚ and 2.97 A˚) and
Gln292 residues (with a distance of 2.57 A˚) and hydrophobic
interactions established by Tyr82, Asp241, Leu242, Asn244,
Trp255, Tyr252, Ile259, Met280, Ser291 and Phe295 residues.
Similar results were observed for compound 2. As shown in
Figure 4, the flavonoid establishes hydrogen bonds formed
by Thr256 (with a distance of 3.04 A˚ and 2.87 A˚) and Gln292
(with a distance of 2.57 A˚) residues and hydrophobic inter-
actions established by Tyr82, Asp241, Leu242, Tyr252, Ile259,
Met280, Ser291, and Phe295 residues. Moreover, in order
to rationalize the binding mode of compounds 1 and 2, we
have used the crystal structure of PDE1 linked to caffeine, a
nonselective PDE inhibitor.The docking analysis was carried
out through LIGPLOT+ version v.1.4.5, PyMOL version 1.7.2,
and discovery studio visualizer version 4.0 software [42, 43].
The analysis of receptor ligand complex based on the hydro-
gen bond interaction and hydrophobic interaction shows that
both compounds displayed a stronger interaction with PDE1
binding site compared with those of caffeine (Figure 5). In
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Figure 5: Superimposition of 1 and 2 (colored by green) and caffeine
(colored by red) in the binding site of PDE1.
particular, the docking result of compounds 1 and 2 on PDE1
shows a binding energy of −7.9 kcal/mol and −7.8 kcal/mol,
respectively, whereas the total energy was of −110 kcal/mol
and−102 kcal/mol.These scores weremuch lower than that of
caffeine (−6.3 kcal/mol; −73 kcal/mol) indicating that the two
tested flavonoids possess higher PDE1 activity.
4. Conclusions
The results of our study show that the methanolic extract of
Pistacia integerrima and two of its constituents exhibited a
PDE1 inhibitory activity in vitro. These evidences were also
supported by docking studies suggesting that their estab-
lished interactions with PDE1 are sufficient to justify the
phosphodiesterase inhibitory activity. Taken together, our
results add new knowledge of chemical constituents respon-
sible for biological activity of P. integerrima and contextually
legitimate the use of this plant in folk medicine.
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